Vimarsana
Biggest News Aggregation in the World

Good Manufacturing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Good Manufacturing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Good Manufacturing Today - Breaking & Trending Today

NanoViricides, Inc.: A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More - Vimarsana News

NanoViricides, Inc.: A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

Novel Host-Mimetic, Virus Killing Technology Platform SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum

NanoViricides, Inc.: NanoViricides Bolsters Partnership Efforts - Vimarsana News

NanoViricides, Inc.: NanoViricides Bolsters Partnership Efforts

SHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it has engaged

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Po - Vimarsana News

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Po

NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of N...

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock - Vimarsana News

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock

SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon.The Phase 1 clinical trial, protocol number...

1MD Nutrition Joins Hands With The Arthritis Foundation To Address Healthy Movement; The Relationship Kicks Off May, 2024 During Arthritis Awareness Month - Vimarsana News

1MD Nutrition Joins Hands With The Arthritis Foundation To Address Healthy Movement; The Relationship Kicks Off May, 2024 During Arthritis Awareness Month

/PRNewswire/ -- 1MD Nutrition, a leading developer of physician-formulated, condition-specific nutritional supplements with key ingredients in therapeutically...